• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Aardvark Therapeutics Inc (AARD)

Common Shares
Sell: $3.83|Buy: $3.98|Change: 0.04 (1.03%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Address




Website

https://www.aardvarktherapeutics.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Aardvark Therapeutics Inc Fourth Quarter Earnings Results for 20262027-03-23T00:00:00
Aardvark Therapeutics Inc Annual Report for 20262027-03-23T00:00:00
Aardvark Therapeutics Inc Third Quarter Earnings Results for 20262026-11-13T00:00:00
Aardvark Therapeutics Inc Second Quarter Earnings Results for 20262026-08-13T00:00:00
Aardvark Therapeutics Inc First Quarter Earnings Results for 20262026-05-14T00:00:00
Aardvark Therapeutics Inc Annual General Meeting for 20252026-04-14T00:00:00

Previous key dates

NameKey Date
Aardvark Therapeutics Inc Annual General Meeting for 20252026-04-14T00:00:00
Aardvark Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-23T00:00:00
Aardvark Therapeutics Inc Annual Report for 20252026-03-23T00:00:00
Evercore ISI 8th Annual Healthcare Conference2025-12-04T11:15:00
Piper Sandler 37th Annual Healthcare Conference2025-12-03T08:00:00
TD Cowen Treatment Advancements in Obesity & Related Disorders Summit2025-11-24T15:00:00
Aardvark Therapeutics Inc Third Quarter Earnings Results for 20252025-11-13T00:00:00
Stifel 2025 Healthcare Conference2025-11-11T16:40:00
Stifel 2025 Virtual Cardiometabolic Forum2025-09-30T09:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-10T10:30:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T07:00:00
Cantor Fitzgerald Global Healthcare Conference2025-09-03T11:30:00
Aardvark Therapeutics Inc Second Quarter Earnings Results for 20252025-08-13T00:00:00
2025 RBC Capital Markets Global Healthcare Conference2025-05-21T14:35:00
H.C. Wainwright 3rd Annual BioConnect Investor Conference2025-05-20T15:30:00
Bank of America Global Healthcare Conference 20252025-05-15T12:35:00
Aardvark Therapeutics Inc First Quarter Earnings Results for 20252025-05-14T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.